Next Article in Journal
Coenzyme Q10 and Neurological Diseases
Next Article in Special Issue
Oxytocin: Old Hormone, New Drug
Previous Article in Journal / Special Issue
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2009, 2(3), 125-133;

Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension

Academic Medical Centre, Amsterdam, The Netherlands
Albert Schweitzer Hospital, Dordrecht, The Netherlands
Author to whom correspondence should be addressed.
Received: 26 November 2009 / Accepted: 30 November 2009 / Published: 1 December 2009
(This article belongs to the Special Issue Antihypertensive Drugs)
Full-Text   |   PDF [201 KB, uploaded 2 December 2009]   |  


Background: Combination therapy with antihypertensive agents utilises different mechanisms of action and may be responsible for a more effective decrease in blood pressure. Objective: To review the recently published trials on efficacy and safety of the combination therapy with olmesartan and amlodipine. Results: The double-blind American COACH (Combination of Olmesartan Medoxomil and Amlopdine Besylate in Controlling High Blood Pressure) study (2008) showed in 1,940 patients that after eight weeks of treatment the BP goals were most frequently achieved in the ‘combination therapy group’, with 56.3% (54.1–58.5%) and 54.0% (51.8–56.2%) of patients reaching adequate blood pressure of <140/90 mmHg with olmesartan/amlodipine 20/10 and 40/10 respectively. Combination therapy was generally well tolerated. The most common side effect was oedema [olmesartan 20 mg 9.9% (8.6–11.3%), amlodipine 10 mg 36.8% (34.7–39.0%), placebo 12.3% (10.9–13.8%)]. The frequency of oedema was lower in the groups combining amlodipine 10 mg with olmesartan 10 mg (26.5%, 24.5–28.5%), 20 mg (25.6%, 23.7–27.6%) or 40 mg (23.5%, 21.6–25.4%). In 2009 three double-blind controlled European studies including 500–1,000 patients each and performed independently of one another have confirmed the above study, and have demonstrated similar efficacy-safety effects from the combination of olmesartan medoxomil with amlodipine, particularly for patients not achieving adequate blood pressure control with olmesartan monotherapy. Conclusions: Combinations of olmesartan and amlodipine were significantly more effective at reducing blood pressure and realising guideline blood pressure goals in patients with mild to severe hypertension than monotherapy (with a placebo component). Combination therapy is well tolerated and is associated with a lower incidence of side effects, such as oedema, compared to monotherapy with high amlodipine dosages (10 mg). View Full-Text
Keywords: olmesartan; amlodipine; combination therapy; hypertension olmesartan; amlodipine; combination therapy; hypertension

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Niemeijer, M.G.; Cleophas, T.J. Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension. Pharmaceuticals 2009, 2, 125-133.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top